Data coverage, completeness and provenance for ARGENT BIOPHARMA LIMITED in the Stock Market API — Health Care · Drug Manufacturers - Specialty & Generic.
Source date: 2026-10-30T02:09:53. Source: yfinance. Collection time is shown separately and does not establish a trade date.
| Date | Close | Currency | Source | Adjustment basis |
|---|---|---|---|---|
| 2026-10-30 | 0.0250 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-29 | 0.0240 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-28 | 0.0270 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-27 | 0.0250 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-26 | 0.0290 | AUD | yfinance | Split- and dividend-adjusted close |
GET /api/v1/companies/RGT/prices · Price parameters and adjustment semantics
Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and the United Kingdom. The company's principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the relief of Dementia and Alzheimer's. It is also involved in the preclinical development of Irnicann for the treatment of Glioblastoma Multiforme; and R&D, which focuses on wound management. The company was formerly known as MGC Pharmaceuticals Limited and changed its name to Argent BioPharma Limited. Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.
Website: https://argentbiopharma.com · Profile fields populated: 60%
Share of stored fields populated in the anchor reporting period (FY2026), primary source yfinance. Full per-field breakdown: GET /api/v1/companies/RGT/financials.
Stored values for the most recent fiscal-year periods, with per-period field counts and the primary source each period came from. Values are shown at reported scale without interpretation.
| Period | Period end | Revenue | Net income | Total assets | Total equity | Fields populated | Source |
|---|---|---|---|---|---|---|---|
| FY2026 (AUD) | 2026-06-30 | 27 | yfinance | ||||
| FY2025 (AUD) | 2025-06-30 | 30 | yfinance | ||||
| FY2024 (AUD) | 2024-06-30 | 30 | yfinance | ||||
| FY2023 (AUD) | 2023-06-30 | 30 | yfinance | ||||
| FY2022 (AUD) | 2022-06-30 | 30 | yfinance |
The endpoints below describe available datasets for this listing. Missing fields remain unknown. Free API keys — no card required.
Name, sector, industry, HQ, employees, market cap, source-tagged.
GET /api/v1/companies/RGT
Multi-year statements with per-field source tags and completeness.
GET /api/v1/companies/RGT/financials
P/E, P/B, ROE, ROA, margins, EPS, debt/equity — formulas documented.
GET /api/v1/companies/RGT/metrics/summary
Report PDFs with LLM-ready markdown conversions where available.
GET /api/v1/companies/RGT/filings
Dated press releases and announcements with source links.
GET /api/v1/companies/RGT/news
Create a free key, then:
curl -H "X-API-Key: KEY" https://stockmarketapi.ai/api/v1/companies/RGT
Free tier — instant API key. Built for AI agents.